A number of research firms have changed their ratings and price targets for Bayer (FRA: BAYN):

  • 2/12/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 2/6/2018 – Bayer was given a new €140.00 ($172.84) price target on by analysts at Baader Bank. They now have a “buy” rating on the stock.
  • 2/5/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 2/2/2018 – Bayer was given a new €129.00 ($159.26) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 1/30/2018 – Bayer was given a new €128.00 ($158.02) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 1/29/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
  • 1/24/2018 – Bayer had its “buy” rating reaffirmed by analysts at DZ Bank AG.
  • 1/23/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at Goldman Sachs Group Inc. They now have a “buy” rating on the stock.
  • 1/22/2018 – Bayer was given a new €100.00 ($123.46) price target on by analysts at Barclays PLC. They now have a “sell” rating on the stock.
  • 1/19/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 1/17/2018 – Bayer had its “buy” rating reaffirmed by analysts at Citigroup Inc.
  • 1/17/2018 – Bayer was given a new €129.00 ($159.26) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 1/16/2018 – Bayer was given a new €125.00 ($154.32) price target on by analysts at Jefferies Group LLC. They now have a “buy” rating on the stock.
  • 1/15/2018 – Bayer had its “buy” rating reaffirmed by analysts at UBS Group AG.
  • 1/12/2018 – Bayer was given a new €120.00 ($148.15) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 1/11/2018 – Bayer had its “buy” rating reaffirmed by analysts at Citigroup Inc.
  • 1/11/2018 – Bayer was given a new €121.00 ($149.38) price target on by analysts at Warburg Research. They now have a “neutral” rating on the stock.
  • 1/10/2018 – Bayer was given a new €128.00 ($158.02) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 1/9/2018 – Bayer was given a new €124.00 ($153.09) price target on by analysts at Commerzbank Ag. They now have a “buy” rating on the stock.
  • 1/4/2018 – Bayer was given a new €131.00 ($161.73) price target on by analysts at Sanford C. Bernstein. They now have a “buy” rating on the stock.
  • 1/4/2018 – Bayer was given a new €128.00 ($158.02) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 1/3/2018 – Bayer was given a new €100.00 ($123.46) price target on by analysts at Barclays PLC. They now have a “sell” rating on the stock.
  • 1/2/2018 – Bayer had its “neutral” rating reaffirmed by analysts at Nord/LB.
  • 12/29/2017 – Bayer was given a new €128.00 ($158.02) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 12/27/2017 – Bayer had its “neutral” rating reaffirmed by analysts at Nord/LB.

Bayer AG (FRA BAYN) opened at €96.93 ($119.67) on Wednesday. The stock has a market cap of $79,990.00 and a PE ratio of 22.91. Bayer AG has a twelve month low of €93.30 ($115.19) and a twelve month high of €123.82 ($152.86).

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.